10Mar
09Mar
Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression in...
02Mar
Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8 at 10:40 a.m. ET in Boston, MA. Read more >>
18Jan
Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
Corbus Pharmaceuticals Holdings, Inc. (CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union ("EU") for the Company's novel synthetic oral endocannabinoid-mimetic drug, JBT-101 ("Resunab") for the treatment of systemic sclerosis. Read more >>
18Jan
Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>
31Dec
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
Corbus Pharmaceuticals Holdings, Inc. CRBP , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF). Read more >>
26Dec
Shares Bringing Holiday Cheer For Investors: Corbus Pharmaceuticals Holdings, Inc.
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have climbed in the previous month. During that time period, shares are up 6.88% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.27%. Year-to-date, the stock has performed 418.18%. Read more >>
23Nov
Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)
On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>
15Nov
Tiny Corbus posts midstage win–just–with resunab in systemic sclerosis
The little-known small cap Corbus Pharmaceuticals ($CRBP), last year touted as a rival to Vertex ($VRTX), has published positive top-line results from its experimental med resunab in patients with a disease that can cause major fibrosis throughout the body. Read more >>
19Oct